Monoclonal antibody improves hidradenitis suppurativa by 55%
Drug Discovery World
FEBRUARY 16, 2024
UCB has revealed new data demonstrating a 55% improvement in adults with moderate to severe hidradenitis suppurativa (HS) treated with monoclonal antibody bimekizumab. The post Monoclonal antibody improves hidradenitis suppurativa by 55% appeared first on Drug Discovery World (DDW).
Let's personalize your content